Study of the Medullary Microenvironment in Acute Childhood Leukemia

Launched by UNIVERSITY HOSPITAL, TOURS · Mar 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the bone marrow environment in children with acute leukemia, which is a type of cancer. The goal is to understand why some children do not respond to treatment and may experience a relapse or worse outcomes. The trial is open to children aged 1 to 15 who have just been diagnosed with either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) and have not yet received treatment. There is also a control group for children undergoing orthopedic surgery who do not have any blood-related illnesses.

Participants in the study will have some tests done on their bone marrow to help researchers learn more about the disease. It's important that both parents or guardians give their consent for their child to participate. This trial is actively recruiting participants, and it seeks to provide valuable insights that could improve treatment for future patients. If you think your child might qualify or you have questions, please talk to your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * for patients with AL:
• • 1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
• • 2. Not having received prior hematological treatment
• • 3. Aged 1 to 15 years old
• • 4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
• • 5. Affiliated patient or beneficiary of a social security scheme.
• * Control group patients:
• • 1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
• • 2. Aged between 1 and 15 years old.
• • 3. Having no pathology of hematological origin.
• • 4. Not having received any treatment that could interfere with the functioning of the bone marrow.
• • 5. Whose 2 parents or the holder of parental authority have signed a consent enlightened.
• • 6. Affiliated patient or beneficiary of a social security scheme.
• Exclusion Criteria:
• * for patients with AL:
• • 1. Patient under 1 year old and over 15 years old.
• • 2. Contraindication to myelogram.
• • 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
• • 4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
• • 5. Having received prior hematological treatments.
• • 6. Parents with physical or mental condition not allowing to understand the informed consent.
• • Control group patients
• • 1. Patient under 1 year old and over 15 years old.
• • 2. Having an underlying haematological pathology.
• • 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
• • 4. Having received prior hematological treatments.
• • 5. Parents with physical or mental condition not allowing to understand informed consent.